Abstract:Rationale: Neuroblastoma is a common abdominal malignancy in children. The chemoresistant and relapsed cases have poor prognosis. The genetic background and the mechanism of resistance remain unelucidated. Next-generation sequence (NGS) is becoming a popular tool to unravel the genetic background and to guide precision medicine in oncology studies as well as in clinical practice. Patient concerns: Here we report a neuroblastoma case of a boy aged 2 years and 8 months when first diagnosed, with multiple metastatic sites found in both lungs. The metastatic tumors were resistant to chemotherapy and the patient suffered from severe bone marrow suppression. NGS of the whole exon revealed somatic mutations including 9666 single-nucleotide variants (SNVs) from 5148 genes, 55 copy number variations (CNVs), and 140 insertion-deletion variations. The high frequency of SNVs makes it distinguished case. However, no mutation of key tumor driver genes with functional significance was identified. No abnormality was found in nucleic acid synthesis enzymes. No amplification of c-Myc and n-Myc was found by fluorescence in situ hybridization (FISH). Both NGS and immunohistochemistry (IHC) analysis indicated that DNA mismatch repair (MMR) system was intact. Interventions: After initial diagnosis, the patient received combinational chemotherapy, which includes vindesine, an analogue of adriamycin suggested by NGS data, for 4 months. Radical section of the tumor together with the left kidney and the left adrenal gland was performed 5 months after diagnosis. Postsurgical chemotherapy protocols was similar with the previous. Outcomes: The patient died 2 years after initial diagnosis after 8 relapses following combinational chemotherapy. Lessons: This case of neuroblastoma is with pronounced somatic mutations but unidentified driver gene and therapeutic target. AlthoughNGSis a potentially powerful tool to guideprecision medicine, at current stage, its application in the clinic certainly has its limits. The underlying mechanism of the substantially increased SNV number, as well as the malignant behaviors of the tumor, is yet to be revealed.

Research frontiers and reflections on neuroblastoma

Research advances of MYCN and ALK gene-related targeted drugs in the treatment of neuroblastoma

Recent advances in molecular genetic characterization of high-risk neuroblastoma

Pathogenesis, Biomarkers and Therapeutic Targets

Advancing therapy for neuroblastoma

Neuroblastoma: clinical and biological approach to risk stratification and treatment

Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions

Nanotechnology-Based Diagnostic and Therapeutic Strategies for Neuroblastoma

Progress of Oncolytic Virotherapy for Neuroblastoma

Molecular Basis and Clinical Features of Neuroblastoma

Research therapeutic advances of oncolytic virus for neuroblastoma

Current Status and Future Perspective on Molecular Imaging and Treatment of Neuroblastoma

[Advances in Basic and Translational Research in Neuroendocrine Neoplasms].

Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors

A highly malignant case of neuroblastoma with substantial increase of single-nucleotide variants and normal mismatch repair system: A case report.

Advances in Neuroblastoma Immunotherapy Based on Chimeric Antigen Receptor

Research status and development trends of omics in neuroblastoma a bibliometric and visualization analysis

Modern surgical strategies in pediatric neuroblastoma: Evolving approaches and treatment principles

MicroRNAs in Neuroblastoma: Small-Sized Players with a Large Impact.

Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma

Revisiting Neuroblastoma: Nrf2, NF-κB and Phox2B as a Promising Network in Neuroblastoma